Avidity Partners logo

Avidity Partners

Crunchbase
Pitchbook
Crunchbase

Deals on record

6

Common Fundraising Type

Series B

Sirona Medical provides a cloud-native radiology workflow solution that integrates diagnostic and clinical image viewing, radiology reporting, and AI capabilities into a single platform.

Series C
$42M
11/26/2024
Article
Aktis Oncology logo
Aktis Oncology

Biotechnology

RA Capital Management logo
RTW Investments logo
Janus Henderson Investors logo
T. Rowe Price Associates logo
MRL Ventures Fund logo
Eli Lilly and Company logo
Bristol Myers Squibb logo
Avidity Partners logo

Aktis Oncology is a clinical-stage biotechnology company developing a proprietary radiopharmaceutical pipeline, including Nectin-4-targeted miniprotein radioconjugates, for cancer treatment.

Series B
$175M
09/30/2024
Article
858 Therapeutics logo
858 Therapeutics

Biotechnology

Avidity Partners logo
Versant Ventures logo
NEA logo
Mirae Asset Capital logo
Logos Capital logo
Insight Partners logo
Alexandria Venture Investments logo

858 Therapeutics is a biotechnology company developing small molecule therapeutics for oncology and immunology, with a lead asset, ETX-19477, in Phase 1 trials for advanced solid tumors.

Series B
$50M
09/26/2024
Article
Helaina logo
Helaina

Biotechnology

Avidity Partners logo
Spark Capital logo
Relish Works logo
Primary Venture Partners logo
Ingeborg Investments logo
Heron Rock logo
Siam Capital logo
CF Private Equity logo

Helaina is a biotechnology company that uses precision fermentation technology to develop human equivalent bioactive proteins, including a novel ingredient for women's health, active nutrition, and healthy aging.

Series B
$45M
09/25/2024
Article
Calyxo logo
Calyxo

Medical Device

Avidity Partners logo
Questa Capital logo
CRG logo

Calyxo, Inc. is a medical device company specializing in the development of the CVAC Aspiration System, an innovative technology aimed at improving kidney stone treatment by reducing residual stone burden.

Series D
$50M
12/12/2023
Article
MBrace Therapeutics logo
MBrace Therapeutics

Biopharmaceutical

Venrock logo
Cowen Healthcare Investments logo
Avidity Partners logo
Alta Partners logo
TPG logo

MBrace Therapeutics is a biopharmaceutical company developing a lead antibody-drug conjugate (ADC) candidate, MBRC-101, targeting the EphA5 receptor tyrosine kinase present in various cancers, with the recent completion of an $85 million Series B financing round.

Series B
$85M
11/14/2023
Article